HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals Inc., (NASDAQ: SPPI) a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, today announced the appointment of Jeffrey Vacirca, MD, FACP to its Board of Directors.
Dr. Vacirca is a practicing oncologist and the current president of the Community Oncology Alliance, an advocacy group focused on supporting community oncology clinics. Additionally, Dr. Vacirca is the medical director of the nation’s largest community oncology group purchasing organization, International Oncology Network and the CEO and managing partner at North Shore Hematology Oncology Associates. He also serves as the vice chairman at Odonate Therapeutics (NASDAQ: ODT), an oncology company focused on treating metastatic breast cancer. Furthermore, he has joined the Board of Directors for One Oncology, an oncologist-led company providing oncologists with innovative tools to help keep cancer care in the hands of the providers.
“As a prominent leader within community oncology, Dr. Vacirca has a reputation and clear understanding of how to successfully develop and commercialize oncology pharmaceuticals,” said Joe Turgeon, President and Chief Executive Officer of Spectrum Pharmaceuticals. “His expertise working across multiple stakeholders including patient advocacy groups, clinical investigators, group purchasing organizations, and government agencies is invaluable and precisely what is needed as Spectrum advances its two late-stage pipeline products, poziotinib and ROLONTIS.”
“Joining the Spectrum Board provides me the rare opportunity to fulfill a passion for patient care while working with a company developing life changing therapies,” said Dr. Vacirca. “Poziotinib has the potential to change the treatment paradigm for a subset of cancer patients that have had no adequate treatment options. Additionally, Spectrum has developed a novel G-CSF, which is the first new drug in over fifteen years for use in chemotherapy induced neutropenia.”
With Dr. Vacirca’s appointment, the Spectrum Board increases to nine directors, each of whom are nominated annually by the nominating and corporate governance committee.
About the Spectrum’s Late-Stage Pipeline
Spectrum Pharmaceuticals has two promising late-stage therapies including poziotinib, an investigational therapy targeting the exon 20 insertion mutation. There are currently no FDA approved targeted therapies for the exon 20 mutation. Poziotinib is currently being studied in a pivotal, multicenter Phase 2 trial for non-small cell lung cancer for patients with the exon 20 mutation. Recent data from an MD Anderson Phase 2 study of poziotinib demonstrated strong efficacy in metastatic, heavily pretreated EGFR and HER2 exon 20 mutant NSCLC patients. The second late-stage pipeline product, ROLONTIS® (eflapegrastim), is a novel G-CSF therapy being investigated for use in chemotherapy induced neutropenia. Spectrum Pharmaceuticals plans to file a BLA submission with the FDA for ROLONTIS by the end of 2018.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs and has an advanced stage pipeline that has the potential to transform the company. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® and ROLONTIS® are registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
© 2018 Spectrum Pharmaceuticals, Inc. All Rights Reserved